NasdaqGS:TWSTBiotechs
Twist Bioscience (TWST) Is Down 5.1% After Upsized Equity Raise And Guidance Hike Has The Bull Case Changed?
Earlier this month, Twist Bioscience completed a US$300.0 million follow-on common stock offering at US$96.00 per share, shortly after filing for a US$250.0 million raise, alongside reporting third-quarter 2026 sales of US$118.38 million and a loss of US$35.05 million.
The company also raised its full-year 2026 revenue guidance to US$456.0 million–US$457.0 million and signaled continued sequential growth across key product lines.
Next, we’ll examine how Twist Bioscience’s upgraded full-year...